New Drug Approved for Early Alzheimer’s
Posted inAlzheimer's Disease Biogen Inc Brain Clinical Trials Dementia Drugs (Pharmaceuticals) Eisai Co Ltd Eli Lilly and Company Food and Drug Administration Leqembi (Drug) Memory Placebos Prices (Fares, Fees and Rates) your-feed-healthcare your-feed-science

New Drug Approved for Early Alzheimer’s

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
FDA Panel Rejects Use of MDMA for Treatment of PTSD
Posted inAmerican Psychiatric Assn Drug Abuse and Traffic Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration Institute for Clinical and Economic Review Justice Department Lykos Therapeutics Medicine and Health Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Placebos Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Therapy and Rehabilitation Veterans your-feed-healthcare

FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws
Posted inAlternative and Complementary Medicine American Psychiatric Assn Clinical Trials Depression (Mental) Drug Abuse and Traffic Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration MAPS Public Benefit Corp Mental Health and Disorders Placebos Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws

The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.